Abeona Therapeutics® Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Rhea-AI Summary
Abeona Therapeutics (Nasdaq: ABEO) announced restricted stock inducement awards for eight newly hired non-executive employees under Nasdaq Listing Rule 5635(c)(4). On April 30, 2026, the Compensation Committee granted awards covering up to 112,621 restricted shares. One-third of each award vests on each anniversary, fully vesting after three years subject to continued employment.
Positive
- None.
Negative
- None.
News Market Reaction – ABEO
In the May 1 session, ABEO declined 0.55%, reflecting a mild negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Apr 07 | Board appointment | Positive | +1.1% | New independent director and Audit Committee chair appointed to the Board. |
| Apr 06 | Inducement grants | Neutral | -1.2% | Equity inducement awards granted to new non‑executive employees under Nasdaq rules. |
| Apr 02 | Commercial expansion | Positive | +5.2% | New Qualified Treatment Center added for ZEVASKYN, expanding patient access. |
| Mar 17 | Earnings & updates | Positive | -3.8% | Full‑year 2025 results and ZEVASKYN launch update following FDA approval. |
| Mar 09 | Business update | Positive | +6.4% | Detailed progress report on ZEVASKYN launch, coverage, and manufacturing activity. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Operational and commercial updates have often seen positive alignment, while earnings drew a negative divergence.
Recent news for Abeona centers on governance, employee incentives and commercialization of ZEVASKYN. A board appointment on Apr 7, 2026 and multiple employee inducement grants, including earlier awards for 8,400 shares, highlight ongoing hiring and governance activity. Commercial progress for ZEVASKYN, including a new Qualified Treatment Center and a detailed business update, was associated with price gains of 5.24% and 6.39%. Full‑year 2025 results, despite outlining revenue of $5.8M and $191.4M in cash and investments, coincided with a -3.84% move.
Key Terms
nasdaq listing rule 5635(c)(4) regulatory
restricted stock financial
vesting financial
AI-generated analysis. How Rhea-AI works. Not financial advice.
CLEVELAND, May 01, 2026 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced it has granted equity awards to new non-executive employees who joined the Company. The equity awards were approved in accordance with Nasdaq Listing Rule 5635(c)(4).
On April 30, 2026, the Compensation Committee of Abeona’s Board of Directors granted restricted stock equity awards as a material inducement to employment to eight individuals hired by Abeona, which equity awards relate to, in the aggregate, up to 112,621 restricted shares of Abeona common stock. One-third of the shares subject to such restricted stock awards will vest yearly on each anniversary of the grant date, such that the shares subject to such restricted stock awards granted to each employee will be fully vested on the third anniversary of the Grant Date, in each case, subject to each employee’s continued employment with Abeona on the applicable vesting dates.
About Abeona Therapeutics
Abeona Therapeutics Inc. is a commercial-stage biopharmaceutical company developing cell and gene therapies for serious diseases. Abeona’s ZEVASKYN® (prademagene zamikeracel) is the first and only autologous cell-based gene therapy for the treatment of wounds in adults and pediatric patients with recessive dystrophic epidermolysis bullosa (RDEB). The Company’s fully integrated cell and gene therapy cGMP manufacturing facility in Cleveland, Ohio serves as the manufacturing site for ZEVASKYN commercial production. The Company’s development portfolio features adeno-associated virus (AAV)-based gene therapies for ophthalmic diseases with high unmet medical need. Abeona’s novel, next-generation AAV capsids are being evaluated for a variety of devastating diseases. For more information, visit www.abeonatherapeutics.com.
ZEVASKYN®, Abeona Assist®, Abeona Therapeutics®, and their related logos are trademarks of Abeona Therapeutics Inc.
Forward-Looking Statements
This press release contains certain statements that are forward-looking within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and that involve risks and uncertainties. We have attempted to identify forward-looking statements by such terminology as “may,” “will,” “believe,” “anticipate,” “expect,” “intend,” “potential,” and similar words and expressions (as well as other words or expressions referencing future events, conditions or circumstances), which constitute and are intended to identify forward-looking statements. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, numerous risks and uncertainties, including but not limited to, our ability to successfully commercialize and market ZEVASKYN, including manufacturing sufficient batches of ZEVASKYN to meet demand; the therapeutic potential of ZEVASKYN; whether the unmet need and market opportunity for ZEVASKYN are consistent with the Company’s expectations; continued interest in our rare disease portfolio; our ability to enroll patients in clinical trials; the outcome of future meetings with and inspections by the FDA or other regulatory agencies, including those relating to preclinical programs and to the cGMP manufacturing of ZEVASKYN; the ability to achieve or obtain necessary regulatory approvals for our pre-clinical programs; the impact of any changes in the financial markets and global economic conditions, including those resulting from changes to U.S. trade policy, such as current or future tariffs; risks associated with data analysis and reporting; and other risks disclosed in the Company’s most recent Annual Report on Form 10-K and subsequent periodic reports filed with the Securities and Exchange Commission. The Company undertakes no obligation to revise these forward-looking statements or to update them to reflect events or circumstances occurring after the date of this press release, whether as a result of new information, future developments or otherwise, except as required by the federal securities laws.
Contacts:
Investor and Media
Greg Gin
VP, Investor Relations and Corporate Communications
Abeona Therapeutics
ir@abeonatherapeutics.com
Investor
Lee M. Stern
Meru Advisors
lstern@meruadvisors.com
